Amarin Corp. (AMRN) gains 6.3% as major shareholders push for a strategic review to recover value after a dramatic stock drop ...

Amarin Corporation announced the presentation of new in vitro data on eicosapentaenoic acid (EPA) at the American College of Cardiology's Annual Scientific Session & Expo from March 29-31 ...

Corporation announced that additional in vitro mechanistic data with eicosapentaenoic acid, EPA, will be presented at the ...

Bradley Radoff and Michael Torok, the Managing Director of JEC Capital Partners, who collectively own approximately 15M shares of Amarin ...

DUBLIN and BRIDGEWATER, N.J. - Amarin Corporation plc (NASDAQ:AMRN) announced today that it will present new in vitro data on its cardiovascular drug at the upcoming American College of Cardiology ...

While we appreciate Sarissa Capital Management's ("Sarissa") involvement and commitment to the Company, we believe shareholders would be best served by the Board immediately conducting a strategic ...

Radoff and Michael Torok of JEC Capital Partners, along with affiliates known as the Concerned Shareholder Group, who collectively own about 15 million shares of Amarin Corporation plc (NASDAQ ...

the “Concerned Shareholder Group” or “we”), who collectively own approximately 15 million shares of Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”), today issued ...

Institutional investors own 22.25% of the company’s stock. Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...